Table 2 Overall objective response rate of patients at cycle 3 and maintained to cycle 5 or end of treatment.
From: Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma
Timepoint | ITT Population | Evaluable Population |
|---|---|---|
Overall response to treatmenta | (N = 74) | (N = 40) |
Cycle 3, Day 1 | ||
CR | 0 | 0 |
PR | 3 (4.1)b | 3 (7.5) |
SD | 34 (45.9) | 25 (62.5) |
Cycle 5, Day 1 | ||
CR | 0 | 0 |
PR | 3 (4.1) | 3 (7.5) |
SD | 16 (21.6) | 13 (32.5) |
End of treatment or early termination | ||
CR | 0 | 0 |
PR | 2 (2.7) | 1 (2.5) |
SD | 10 (13.5) | 7 (17.5) |